Document is current
Any future updates will be listed below
-
Authors
Schiele, Jessica
Tsai, Pei-Ling https://orcid.org/0000-0003-0233-703X
Schimmele, Tamara
Beck, Sina https://orcid.org/0009-0003-6964-5819
Meyer, Maren
Mannes, Marco
Desmond, Luke W.
Noschka, Reiner
Huber-Lang, Markus
Haffner-Luntzer, Melanie
Jarczok, Marc N.
Lowry, Christopher A. https://orcid.org/0000-0003-3920-5575
Reif, Andreas https://orcid.org/0000-0002-0992-634X
Langgartner, Dominik
Stenger, Steffen
Slattery, David A. https://orcid.org/0000-0001-8753-5005
Reber, Stefan O. https://orcid.org/0000-0002-1583-7618
-
Funding
Funding for this research was provided by:
Deutsche Forschungsgemeinschaft (RE 2911/ 23-1)
Deutsche Forschungsgemeinschaft (German Research 251293561)
Deutsche Forschungsgemeinschaft (German Research 251293561)
Deutsche Forschungsgemeinschaft (SL 141/ 6-1)
- License Information
-
More Information
Article History
Received: 2 September 2025
Revised: 2 April 2026
Accepted: 30 April 2026
First Online: 22 May 2026
Competing interests
: CAL is Cofounder and member of the Board of Directors and Scientific Advisory Board of Mycobacteria Therapeutics Corporation (Kioga) and, in the previous three years, has served as a member of the faculty of Clinical Care Options, LLC (CCO), Reston, Virginia, the Integrative Psychiatry Institute, Boulder, Colorado, the Institute for Brain Potential, Los Banos, California, and Intelligent Health Ltd, Reading, UK. In the previous three years, CAL served on the Scientific Advisory Board of Immodulon Therapeutics Ltd., London, UK. The remaining authors declare that they have no competing interests.
